View More Recent Stories
-
UBS Starts Ideaya Biosciences (IDYA) at Buy
-
Cantor Fitzgerald Starts Ideaya Biosciences (IDYA) at Overweight
-
Goldman Sachs Reiterates Buy Rating on Ideaya Biosciences (IDYA)
-
IDEAYA Biosciences (IDYA) Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer
-
Mizuho Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
-
RBC Capital Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
-
Citi Reiterates Buy Rating on Ideaya Biosciences (IDYA)
-
Ideaya Biosciences (IDYA) PT Raised to $48 at Goldman Sachs
-
Ideaya Biosciences (IDYA) PT Lowered to $66 at Stifel
-
BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
-
IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting
-
Ideaya Biosciences (IDYA) PT Raised to $68 at Stifel
-
Ideaya Biosciences (IDYA) PT Raised to $47 at Goldman Sachs
-
Ideaya Biosciences (IDYA) PT Lowered to $53 at Oppenheimer
-
IDEAYA Biosciences (IDYA) Enters Option and License Agreement with Biocytogen for B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
-
RBC's biotech survey shows investors more bearish vs. last time
-
Ideaya Biosciences (IDYA) PT Raised to $55 at Mizuho
-
Ideaya Biosciences (IDYA) PT Raised to $61 at RBC Capital
-
IDEAYA Biosciences (IDYA) Prices 7.23M Share Offering at $35/sh
-
2Q24 U.S. biotech earnings preview
-
IDEAYA Biosciences (IDYA) Announces Proposed $200M Share and Warrant Offering
-
Citi Reiterates Buy Rating on Ideaya Biosciences (IDYA)
-
Ideaya Biosciences (IDYA) PT Raised to $62 at BTIG
-
Ideaya Biosciences (IDYA) PT Raised to $60 at Oppenheimer
-
Mizuho Starts Ideaya Biosciences (IDYA) at Outperform
-
IDEAYA Biosciences (IDYA) Announces Resignation of Chief Legal Officer
-
IDEAYA Biosciences (IDYA) Issues Clinical Program Updates for IDE397
